Damon R. Reed

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Oncology, Pathology, Advanced Soft-tissue Sarcoma +5

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 293 citations · Full text

Medicine, Randomised Phase 3, Metronomic Therapy +7

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin et al. · Journal of the National Comprehensive Cancer Network · 2018 · 292 citations

Family Medicine, Aya Oncology, Cancer Management +23

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

J. Sybil Biermann, Warren Chow, Damon R. Reed et al. · Journal of the National Comprehensive Cancer Network · 2017 · 291 citations · Full text

Bone Disease, Medicine, Cancer Management +10

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan et al. · Journal of Clinical Oncology · 2019 · 251 citations · Full text